Absolute Bioavailability Study With Bexagliflozin

• Status: Withdrawn
• Trial end date: 2018-09-16
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Theracos
• Treatments: Bexagliflozin

Criteria

Inclusion Criteria:

• body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2

• no nicotine and tobacco consumption in the past 3 months

• willing and able to be confined to the clinical research facility as required by the protocol

Exclusion Criteria:

• clinically significant history of allergy to drugs or latex

• history of alcohol or drug dependence in the past 12 months.

• donation of a significant amount of blood in the past 2 months

• willing to use an adequate form of birth control during the study and for 90 days after discharge from clinic

• exposure to investigational drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer